Categories: CHF

AHA: First data backs AskBio’s heart failure gene therapy

AskBio recently started a phase 2 trial of AB-1002, called GenePHIT, that will compare two doses of AB-1002 to placebo in around 150 patients with NYHA Class III heart failure, with a primary analysis …
Read Full Story at source (may require registration)

Latest posts by Business Editor (see all)
Business Editor

Leave a Comment
Share
Published by
Business Editor
1 year ago

Recent Posts

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

8 hours ago

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

9 hours ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

9 hours ago

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

10 hours ago

Kyndryl Announcement: If You Have Suffered Losses in Kyndryl Holdings, Inc. (NYSE: KD), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor…

10 hours ago

Australian Dollar Speculative Net Positions Improve, But Remain in the Negative

The latest data release from the Commodity Futures Trading Commission (CFTC) reveals a marginal improvement…

16 hours ago

This website uses cookies.